AstraZeneca's (AZN) product, Cozaar, is indicated for the treatment of hypertension and the prevention of cardiovascular events such as heart attack and stroke. The market for Cozaar has been robust and is projected to remain growing at a CAGR of 7.0% from the forecasted fourth quarter 2024 to 2033, driven by several key factors.
The Cozaar product, developed by AstraZeneca, is expected to reach the US healthcare sector market in Q3 2025. Its sales account for approximately $2.1 billion of the company's gross, with the estimated market size reaching $5.1 billion by 2034, growing at a CAGR of 7.0% during the forecast period.
The Cozaar product is segmented based on type, application, and distribution. Cozaar has a high penetration strategy with a steady growth trajectory, with around 80% of the market expected to reach the healthcare sector in the forecast period. The market is dominated by primary and secondary care, where around 15% of the market is expected to reach the healthcare sector in the forecast period. Secondary care markets account for around 4% of the market share, with around 3% expected to reach the healthcare sector in the forecast period.
The Cozaar product is driving growth due to several key factors. The key drivers include:
The Cozaar product is expected to have significant market share in several regions, including North America, Europe, the Middle East, and Africa. North America is anticipated to dominate the market due to high healthcare expenditure, advanced healthcare infrastructure, and high awareness of hypertension prevention and treatment.
Drugmaker GlaxoSmithKline (GSK) has launched an abbreviated new drug application for Cozaar (tamoxifen) in the US, the company said Thursday.
The new drug application was filed by GlaxoSmithKline and the US government in the US in late August.
It is the first US application to launch on the same regulatory pathway to market Cozaar in the same indication. The new drug application is the first of a new class of drugs that is to be approved for off-label use in the United States.
GSK will be marketing Cozaar under the same label and labeling as its other major cholesterol-lowering drugs.
The new drug application will provide generic alternatives to the brand-name drug and will be approved in the US by the Food and Drug Administration (FDA) for the treatment of heart failure and other related heart disease. The drug is used in heart failure due to its anti-hypertensive effect and for the treatment of acute coronary syndrome.
GSK will also be marketing a generic version of the drug, also called Ambrisentan.
The FDA approved the drug for treatment of acute exacerbation of chronic bronchitis in adults and patients with severe pneumonia.
In December, the US Food and Drug Administration (FDA) issued a warning to the public of the potential side effects of Ambrisentan. The company said the potential side effects were similar to those seen with some other drugs, including the drug used to treat ulcers.
GSK's new drug application is an abbreviated new drug application (ANDA), which will be submitted to the FDA in the US for approval.
GSK is not making any payment to the FDA, according to the company. "GSK has been an early adopter of the new drug application."
GSK has already made a payment of $6.5 million to the FDA, but the amount will be split between a $2.5 million and $6 million payment by the FDA.
GSK is also planning to launch a generic version of Ambrisentan as an alternative to the brand-name drug.
The company said it was working on an ANDA for the US market in the coming months.
The company said it will continue to work with the FDA to approve the drug applications for it in the US and to market the brand-name drug to the US market.
GlaxoSmithKline's CEO, John LechleiterGlaxoSmithKline CEO, John Lechleiter, said, "The recent announcement of a generic application for Cozaar for the treatment of heart failure is a welcome sign that we are seeing the launch of more new drugs in the US and in other countries."
The company said the FDA has approved it for the treatment of acute exacerbation of chronic bronchitis in adults and patients with severe pneumonia.
The company said its application to the US market would continue to be submitted to the FDA in the next six months.
GSK is working with the FDA to ensure it receives approval from the agency to launch the new drug application in the US market.
Drugmaker Merck & Co (MSZ) has also made an ANDA for Cozaar, it said in an interview in December. The company said the ANDA would be submitted to the FDA in the next six months.GSK is also working on an ANDA for ambrisentan, which has been approved for use in the US market as an alternative to the brand-name drug.
GSK said the ANDA would be submitted in the same timeframe as the drug applications to be submitted to the FDA in the US market.
GSK said that the company has received approval to launch the drug in the US market in the second half of next year.
You are currently taking Cozaar (losartan) for hypertension (high blood pressure). Tell your doctor or pharmacist if you are not sure whether you are taking Cozaar, or if you have any questions about how to use Cozaar? Ask your doctor or pharmacist. Cozaar can lower blood pressure if taken with a low-salt diet, but Cozaar does not lower blood pressure if you take it with a high-salt diet. You should not take Cozaar if you are taking or have taken Riociguat (Adempas) for high blood pressure (hypertension). Cozaar does not protect against strokes, heart attacks, or other rare conditions such as internal bleeding from the stomach or intestines. Tell your doctor if you are taking Adempas or if you have any questions about the uses of Adempas. Cozaar may also be used to treat high blood pressure or to reduce the risk of stroke in patients at risk of stroke. You should not take Cozaar if you are taking or have taken Riociguat (Adempas).
Cozaar is not usually recommended for people with a body mass index (BMI) of 30 or greater (or of 40 or greater if you are over 30) or a family history of pulmonary arterial hypertension (PAH), and you should not take Riociguat if you are taking or have taken it in the last 6 months. Riociguat is not used in children and adolescents.
Cozaar can increase your risk for a heart attack, and even stroke. Tell your doctor or pharmacist if you are taking any other medicines, including any that you get without a prescription from your pharmacy, or if you have any questions about your medicines, your family history of heart problems or stroke.
Cozaar is not usually recommended for people with a body mass index (BMI) of 30 or greater (or of 40 or greater if you are over 30).
Tell your doctor or pharmacist if you are taking any of the medicines listed below:
You should not take Riociguat if you are taking Riociguat with a high-salt diet or if you are taking Riociguat with Riociguat or any other medicines you get without a prescription. You can take Riociguat with or without food. Riociguat and Riociguat together have the same active ingredient and are delivered through a special delivery system called a ‘prostaglandin-fneumactin lactation system’ (Lilopid). Ask your doctor or pharmacist if you do not understand the meaning of the following words:
Riociguat and Benazepril are medicines that treat high blood pressure. Tell your doctor if you are taking or have taken Riociguat (Adempas).
There are two medicines called losartan and cozaar. They are similar in many ways, but they both increase your blood pressure.
Cozaar is used to reduce the level of certain blood clots in the blood vessels, which causes them to narrow and to be resistant to drugs. It can also be used for the treatment of rheumatoid arthritis and ankylosing spondylitis. It is also used to reduce the chances of strokes and heart attacks. Cozaar is also used in the management of high blood pressure.
The drug is only available in a 10 mg dose and is not an immediate treatment.
The drug is an anti-angina drug. It works by stopping the production of certain chemicals in the body that cause the blood vessels to narrow.
The drug belongs to the group of medicines known as anti-platelet drugs or anti-hypertensive drugs. It lowers the amount of blood pressure by reducing the amount of the chemical that gets into the blood. The blood pressure may be raised by the drug or reduced by the liver.
It is also used for the treatment of high blood pressure.
The most common side effects of Cozaar are:
If you experience any of the above-mentioned side effects, stop taking the drug and contact your doctor.
The drug interacts with the following medicines:
The drug may interact with other drugs.
The drug is not an aphrodisiac and can also reduce sperm count.
The drug is also not recommended for women.
The drug can also have a negative effect on the liver. This is because the drug can make it more difficult for the liver to make a liver-protectin (liver-inhibitor) and thus it can have a negative effect on the liver.
The drug can also affect the kidneys. This is because the drug can make it more difficult for kidneys to remove urine from the body. The drug can also make it more difficult for the liver to take in urine. Therefore, it can affect the kidneys too much.
The drug can also have an effect on the heart. The drug can make it more difficult for the heart to pump blood around the body. This can make the heart too weak, too heavy, too fast, too slow, too often beats too much and can cause the blood pressure to rise and drop.
Stade de France Pharmacy